Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Improving Prediction of Intracranial Aneurysm Rupture Status Using Temporal Velocity-Informatics.

Annals of biomedical engineering·2025

Same author

Augmenting Prediction of Intracranial Aneurysms' Risk Status Using Velocity-Informatics: Initial Experience.

Journal of cardiovascular translational research·2023

Same author

Can we explain machine learning-based prediction for rupture status assessments of intracranial aneurysms?

Biomedical physics & engineering express·2023

Same author

Radiation-Induced Imaging Changes and Cerebral Edema following Stereotactic Radiosurgery for Brain AVMs.

AJNR. American journal of neuroradiology·2020

Same author

Percutaneous fluoroscopically-guided transcervical retrograde access facilitates successful thoracic duct embolization after failed antegrade transabdominal access.

Lymphology·2019

Same author

Setting the Stage for 2018: How the Changes in the American Joint Committee on Cancer/Union for International Cancer Control <i>Cancer Staging Manual</i> Eighth Edition Impact Radiologists.

AJNR. American journal of neuroradiology·2017

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Panitumumab (vectibix).

J J Gemmete¹, S K Mukherji

¹Department of Radiology, Division of Neuroradiology, University of Michigan Health System, Ann Arbor, 48109, USA. gemmete@med.umich.edu

AJNR. American Journal of Neuroradiology

|May 21, 2011

Summary

Panitumumab (Vectibix) is a targeted therapy for metastatic colorectal cancer. It is a monoclonal antibody that inhibits EGFR, offering a treatment option for patients who have progressed on standard chemotherapy.

Area of Science:

Oncology
Pharmacology
Immunology

Background:

Metastatic colorectal carcinoma (mCRC) presents a significant treatment challenge.
Standard chemotherapy regimens (fluoropyrimidine, oxaliplatin, irinotecan) are often followed by disease progression.
Epidermal Growth Factor Receptor (EGFR) is a key target in cancer therapy.

Purpose of the Study:

To elucidate the mechanism of action of panitumumab.
To define the clinical role of panitumumab in mCRC treatment.
To provide a comprehensive overview of this EGFR antagonist.

Main Methods:

Review of preclinical studies on panitumumab's EGFR antagonism.
Analysis of clinical trial data evaluating panitumumab efficacy and safety.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 1, 2026

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Pharmacological assessment of monoclonal antibody activity.

Main Results:

Panitumumab binds to EGFR, inhibiting downstream signaling pathways crucial for tumor growth and survival.
Clinical studies demonstrate panitumumab's efficacy as a single agent in pre-treated mCRC patients.
Adverse events associated with panitumumab are manageable.

Conclusions:

Panitumumab represents a valuable therapeutic option for patients with mCRC.
Its mechanism as an EGFR antagonist provides a targeted approach to treatment.
The clinical role of panitumumab is established in specific patient populations.